Daiwa Securities Group Inc. Acquires 771 Shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT)

Daiwa Securities Group Inc. raised its position in shares of Sarepta Therapeutics, Inc. (NASDAQ:SRPT) by 28.7% in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 3,454 shares of the biotechnology company’s stock after purchasing an additional 771 shares during the period. Daiwa Securities Group Inc.’s holdings in Sarepta Therapeutics were worth $546,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other hedge funds have also added to or reduced their stakes in SRPT. Innealta Capital LLC purchased a new position in Sarepta Therapeutics in the second quarter worth $31,000. Mather Group LLC. purchased a new position in shares of Sarepta Therapeutics during the 1st quarter worth approximately $28,000. Riggs Asset Managment Co. Inc. raised its holdings in Sarepta Therapeutics by 125.0% in the first quarter. Riggs Asset Managment Co. Inc. now owns 225 shares of the biotechnology company’s stock worth $29,000 after purchasing an additional 125 shares in the last quarter. New Covenant Trust Company N.A. bought a new position in shares of Sarepta Therapeutics during the first quarter valued at approximately $32,000. Finally, Principal Securities Inc. purchased a new position in Sarepta Therapeutics during the fourth quarter valued at $26,000. Hedge funds and other institutional investors own 86.68% of the company’s stock.

Wall Street Analyst Weigh In

SRPT has been the subject of a number of research reports. Cantor Fitzgerald reduced their target price on shares of Sarepta Therapeutics from $167.00 to $152.00 and set a “neutral” rating for the company in a report on Thursday, August 8th. Bank of America upped their price target on shares of Sarepta Therapeutics from $166.00 to $213.00 and gave the stock a “buy” rating in a report on Friday, June 21st. Barclays lowered their price objective on shares of Sarepta Therapeutics from $226.00 to $203.00 and set an “overweight” rating for the company in a research note on Thursday, August 8th. Royal Bank of Canada reaffirmed an “outperform” rating and set a $181.00 price objective on shares of Sarepta Therapeutics in a research report on Friday, September 6th. Finally, Morgan Stanley restated an “overweight” rating and set a $165.00 price target on shares of Sarepta Therapeutics in a research note on Friday, June 21st. Three equities research analysts have rated the stock with a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Sarepta Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $186.22.

Sarepta Therapeutics Price Performance

Shares of NASDAQ SRPT opened at $124.33 on Tuesday. Sarepta Therapeutics, Inc. has a 1-year low of $55.25 and a 1-year high of $173.25. The company has a market capitalization of $11.75 billion, a price-to-earnings ratio of 1,130.27 and a beta of 0.81. The company has a debt-to-equity ratio of 1.05, a current ratio of 3.90 and a quick ratio of 3.19. The business has a 50-day moving average of $139.24 and a 200-day moving average of $132.69.

Sarepta Therapeutics (NASDAQ:SRPT) last announced its quarterly earnings results on Wednesday, August 7th. The biotechnology company reported $0.07 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.01 by $0.06. Sarepta Therapeutics had a return on equity of 5.32% and a net margin of 3.14%. The business had revenue of $362.90 million for the quarter, compared to the consensus estimate of $394.38 million. During the same quarter last year, the business posted ($0.27) EPS. The business’s revenue was up 38.9% on a year-over-year basis. On average, equities analysts anticipate that Sarepta Therapeutics, Inc. will post 1.47 EPS for the current fiscal year.

Insider Activity at Sarepta Therapeutics

In other news, Director Michael Andrew Chambers acquired 37,038 shares of the firm’s stock in a transaction that occurred on Friday, August 16th. The stock was purchased at an average price of $133.80 per share, with a total value of $4,955,684.40. Following the purchase, the director now owns 284,034 shares of the company’s stock, valued at approximately $38,003,749.20. The purchase was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. In other news, CFO Ian Michael Estepan sold 5,985 shares of the stock in a transaction that occurred on Friday, August 30th. The stock was sold at an average price of $137.36, for a total value of $822,099.60. Following the completion of the sale, the chief financial officer now directly owns 33,946 shares of the company’s stock, valued at $4,662,822.56. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Michael Andrew Chambers purchased 37,038 shares of the business’s stock in a transaction on Friday, August 16th. The stock was purchased at an average cost of $133.80 per share, with a total value of $4,955,684.40. Following the acquisition, the director now owns 284,034 shares in the company, valued at $38,003,749.20. The disclosure for this purchase can be found here. Insiders sold 52,801 shares of company stock valued at $8,399,586 over the last 90 days. 7.70% of the stock is currently owned by corporate insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.